Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: An open label trial

• Published in: Journal of affective disorders Vol. 173; pp. 216 - 220
• Main Authors: McGirr, Alexander, Van den Eynde, Frederique, Tovar-Perdomo, Santiago, Fleck, Marcelo P.A, Berlim, Marcelo T
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-03-2015
• Subjects: Accelerated rTMS; Adult; Antidepressive Agents - therapeutic use; Combined Modality Therapy; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - therapy; Depressive Disorder, Treatment-Resistant - drug therapy; Depressive Disorder, Treatment-Resistant - therapy; Female; High-frequency rTMS; Humans; Major depressive disorder; Male; Middle Aged; Open-label trial; Psychiatry; Quality of Life; RTMS; Transcranial Magnetic Stimulation - methods; Treatment Outcome; Treatment resistant depression; Accelerated rTMS; Open-label trial; Treatment resistant depression; High-frequency rTMS; Major depressive disorder; RTMS
• ISSN: 0165-0327; 1573-2517
• DOI: 10.1016/j.jad.2014.10.068

Abstract Background Major depressive disorder (MDD) is a significant cause of worldwide disability and treatment resistance is common. High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) has emerged as a treatment for MDD, and while efficacious, the daily commitment for typical 4–6 weeks of treatment poses a significant challenge. We aimed to determine the effectiveness and acceptability of an accelerated rTMS protocol for MDD. Methods In this naturalistic trial, 27 patients with moderate to severe chronic and treatment-resistant MDD were treated with twice-daily HF-rTMS (10 Hz) applied over the left dorsolateral prefrontal cortex for 2 consecutive weeks (60,000 pulses). The primary outcomes were rates of clinical remission and response (16-item Quick Inventory of Depressive Symptomatology post-treatment score ≤6, and≥50% reduction, respectively). Secondary outcomes were self-reported anxious symptoms, depressive symptoms and quality of life, and dropout rates as a proxy for acceptability. Results Ten (37.0%) patients met criteria for clinical remission and 15 (55.6%) were classified as responders, with comparable outcomes for both moderate and severe MDD. Clinician-rated improvements in depressive symptoms were paralleled in self-reported depressive and anxious symptoms, as well as quality of life. No patient discontinued treatment. Limitations This study is limited by short treatment duration that might be lengthened with corresponding improvements in effectiveness, limited duration of follow-up, small sample size, and an open-label design requiring randomized controlled replication. Conclusion An accelerated protocol involving twice-daily sessions of HF-rTMS over the left DLPFC for 2 weeks was effective in treatment-resistant MDD, and had excellent acceptability. Additional research is required to optimize accelerated rTMS treatment protocols and determine efficacy using sham-controlled trials.